Seres Therapeutics Inc (NASDAQ:MCRB) CEO Roger Pomerantz sold 26,492 shares of the firm’s stock in a transaction dated Wednesday, June 20th. The shares were sold at an average price of $9.33, for a total value of $247,170.36. Following the transaction, the chief executive officer now owns 297,812 shares of the company’s stock, valued at $2,778,585.96. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Roger Pomerantz also recently made the following trade(s):
Get Seres Therapeutics alerts: On Friday, June 22nd, Roger Pomerantz sold 40,057 shares of Seres Therapeutics stock. The shares were sold at an average price of $9.36, for a total value of $374,933.52. On Wednesday, May 9th, Roger Pomerantz sold 233 shares of Seres Therapeutics stock. The shares were sold at an average price of $9.00, for a total value of $2,097.00.Seres Therapeutics stock traded up $0.47 during midday trading on Friday, reaching $9.51. 597,401 shares of the stock traded hands, compared to its average volume of 177,517. Seres Therapeutics Inc has a 12-month low of $6.65 and a 12-month high of $17.42. The stock has a market capitalization of $367.50 million, a price-to-earnings ratio of -4.30 and a beta of 0.52. The company has a debt-to-equity ratio of 0.85, a current ratio of 3.60 and a quick ratio of 3.60.
Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Wednesday, May 9th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.06. The company had revenue of $3.97 million for the quarter, compared to analyst estimates of $3.00 million. Seres Therapeutics had a negative return on equity of 150.44% and a negative net margin of 277.79%. equities research analysts anticipate that Seres Therapeutics Inc will post -2.53 earnings per share for the current year.
A number of brokerages recently commented on MCRB. BidaskClub upgraded Seres Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday. ValuEngine upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, June 6th. Finally, Zacks Investment Research cut Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. Seres Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $17.89.
Hedge funds have recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership acquired a new stake in Seres Therapeutics in the 4th quarter valued at about $143,000. Wells Fargo & Company MN raised its position in Seres Therapeutics by 107.2% in the 4th quarter. Wells Fargo & Company MN now owns 29,183 shares of the biotechnology company’s stock valued at $296,000 after purchasing an additional 15,097 shares in the last quarter. A.R.T. Advisors LLC raised its position in Seres Therapeutics by 141.3% in the 1st quarter. A.R.T. Advisors LLC now owns 45,952 shares of the biotechnology company’s stock valued at $337,000 after purchasing an additional 26,909 shares in the last quarter. Virtus Fund Advisers LLC acquired a new stake in Seres Therapeutics in the 4th quarter valued at about $358,000. Finally, Two Sigma Advisers LP raised its position in Seres Therapeutics by 153.6% in the 4th quarter. Two Sigma Advisers LP now owns 35,500 shares of the biotechnology company’s stock valued at $360,000 after purchasing an additional 21,500 shares in the last quarter. 79.53% of the stock is currently owned by institutional investors.
About Seres Therapeutics
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).
